drugset / Trial / NCT04793919

Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia

NCT04793919

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The trial is open to all patients with a diagnosis of acute promyelocytic leukemia (APL) who are PCR-positive for the PML-RARα transcript and less than 18 years of age.

Timeline

Start
2019-10-09
Primary completion
2025-10-09
Completion
2027-10-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemtuzumab Ozogamicin Monoclonal antibody
Subject Tretinoin Small molecule
Subject arsenic trioxide Small molecule